Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 15;87(5):1187-1195.
doi: 10.1097/QAI.0000000000002713.

Early Diagnosis of HIV-1 and HIV-2 Using Cobas HIV-1/HIV-2 Qualitative Test: A Novel Qualitative Nucleic Acid Amplification Test for Plasma, Serum, and Dried Blood Spot Specimens

Lucia Hans  1   2 , Nicole von Allmen  3 , Anke Edelmann  3 , Jörg Hofmann  3 , Alex Y Nilsson  4 , Christian O Simon  5 , Britta Seiverth  6 , Peter Gohl  7 , Sergio Carmona  1   2
Affiliations

Early Diagnosis of HIV-1 and HIV-2 Using Cobas HIV-1/HIV-2 Qualitative Test: A Novel Qualitative Nucleic Acid Amplification Test for Plasma, Serum, and Dried Blood Spot Specimens

Lucia Hans et al. J Acquir Immune Defic Syndr. .

Abstract

Background: Nucleic acid amplification tests (NATs) minimize the time from HIV infection to diagnosis, reducing transmission during acute HIV. NATs are especially useful for diagnosing HIV in children younger than 18 months and discriminating between HIV-1 and HIV-2.

Methods: We evaluated the performance of the cobas HIV-1/HIV-2 qualitative (cobas HIV-1/2 Qual) test for use on cobas 6800/8800 Systems. The results of adult plasma and serum samples and pediatric dried blood spots were compared with those of the recomLine HIV-1 & HIV-2 Immunoglobulin G serological test and COBAS AmpliPrep/COBAS TaqMan HIV-1 qualitative test, v2.0. Genotype inclusivity and limits of detection were determined, and sensitivity on seroconversion panels was compared with that in the Bio-Rad Geenius HIV 1/2 Confirmatory Assay, Abbott ARCHITECT HIV Ag/Ab Combo serological test, and cobas TaqScreen MPX, v2.0.

Results: Concordance of cobas HIV-1/2 Qual test with the comparator serological test and COBAS AmpliPrep/COBAS TaqMan test was ≥99.6% with all sample types. Reactivity with all HIV genotypes was 100%. LOD in plasma samples was 14.8, 12.6, and 27.9 copies/mL for HIV-1 group M, HIV-1 group O, and HIV-2, respectively, with similar results for serum samples. LOD in dried blood spots was 255 copies/mL for HIV-1 and 984 copies/mL for HIV-2. HIV infection was detected 18.9 days and 8.5 days earlier than the confirmatory and serological assays, respectively, and at a similar time to the NAT.

Conclusions: The cobas HIV-1/2 Qual test enables early and accurate diagnoses of HIV-1 and HIV-2 in adults and children across sample types. The assay could help avert transmission during acute HIV, simplify HIV diagnostic algorithms, and promote the survival of HIV-infected children.

PubMed Disclaimer

Figures

FIGURE 1.
FIGURE 1.
Overview of the cobas HIV-1/2 Qual test workflow for DBS.
FIGURE 2.
FIGURE 2.
HIV-1 seroconversion panel results comparing time to diagnosis with the cobas HIV-1/2 Qual test and Bio-Rad Geenius HIV 1/2 Confirmatory Assay.
FIGURE 3.
FIGURE 3.
HIV-1 seroconversion panel results comparing time to diagnosis with the cobas HIV-1/2 Qual test and Abbott ARCHITECT HIV Ag/Ab Combo test.---Average difference in days to reactive (cobas vs ARCHITECT).
See this image and copyright information in PMC

References

    1. UNAIDS. Ending AIDS. Progress towards the 90-90-90 Targets. Global AIDS Update 2017. UNAIDS/JC2900E. 2017. Available at: http://www.unaids.org/sites/default/files/media_asset/Global_AIDS_update.... Accessed June 2019.
    1. UNAIDS. 90-90-90. An Ambitious Treatment Targetto Help End the AIDS Epidemic. UNAIDS/JC2684. 2014. Available at: http://www.unaids.org/sites/default/files/media_asset/90-90-90_en.pdf. Accessed June 2019.
    1. Rutstein SE, Ananworanich J, Fidler S, et al. . Clinical and public health implications of acute and early HIV detection and treatment: a scoping review. J Int AIDS Soc. 2017;20:21579. - PMC - PubMed
    1. Cohen MS, Gay CL, Busch MP, et al. . The detection of acute HIV infection. J Infect Dis. 2010;202suppl 2:S270–S277. - PubMed
    1. Delaney KP, Hanson DL, Masciotra S, et al. . Time until emergence of HIV test reactivity following infection with HIV-1: implications for interpreting test results and retesting after exposure. Clin Infect Dis. 2017;64:53–59. - PubMed

Publication types

MeSH terms